CoChat

SH3-dependent assembly of the phagocyte NADPH oxidase.

Open access
McPhail, L C · 1994 · The Journal of experimental medicine
Cited by 65

The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.

Abstract

F ~hagocytic cells contain a complicated enzyme system, termed NADPH oxidase, that is responsible for the production of toxic oxygen species (1). The enzyme transfers electrons from NADPH to 02, forming O2-, which then can dismutate into H202. Subsequently, other oxygen derivatives, such as hydroxyl radical and hypochlorous acid, may be formed. Collectively, these oxygen products are toxic to components in their environment, either phagocytosed or extracellular microorganisms or surrounding tissue (1, 2). Thus, the NADPH oxidase of phagocytic cells is an important participant in both host defense and inflammatory mechanisms. This is well-illustrated by the genetic disorder, chronic granulomatous disease (CGD), in which the NADPH oxidase enzyme is defective. Patients with CGD suffer from frequent and severe infections, as well as noninfectious complications, such as lymphadenopathy and hepatomegaly (3). Components of NADPH Oxidase. The NADPH oxidase enzyme consists of at least four polypeptide components (1, 3, 4). Two of the components, termed gp91-phox and p22phox, form an unusual heterodimeric cytochrome b, cytochrome bsss. The other two components, termed p47-phox and p67-phox, are cytosolic proteins that assemble with cytochrome bsss during activation of the enzyme. The nomenclature used designates the size of each protein by SDS-PAGE and indicates that each protein is a component of the phagocyte oxidase ("gp" denotes glycoprotein, "p" denotes protein). At least one additional protein, the small GTP-binding protein Rac (either Racl or Rac2), is needed for NADPH oxidase activation (5-7). The mechanism by which GTP-bound Rac influences the enzyme is unknown, but is under intense investigation (8, 9). A sixth oxidase-related protein, termed p40-phox, recently has been identified (10, 11), which has sequence similarity to p47-phox and p67-phox and appears to physically associate with p67-phox. Defects in any of the four genes that code for components of the NADPH oxidase enzyme system can cause CGD (3). In most cases, the gene defect results in the absence of the protein product and, thus, the absence of NADPH oxidase activity. Both gp91-phox and p22-phox are usually absent if either gene is defective, suggesting each is unstable without the other. A few cases have been reported where cytochrome bsss is present, but nonfunctional, and these are usually caused by point mutations in the gene for either gp91-phox or p22-phox. These have been particularly informative for gaining insights into structure/ function relationships, as discussed below. Additional information on the molecular genetics of CGD can be found in recent excellent reviews (3, 12). Activation ofNADPH Oxidas~ NADPH oxidase is inactive until the cell is stimulated by phagocytosis or various inflammatory mediators (e.g., chemoattractants, cytokines). Binding of an agonist to its cell-surface receptor triggers various signal transduction pathways (13). While a number of signaling intermediates (e.g., phospholipases, protein kinases) have been implicated as regulators of NADPH oxidase activation, a complete pathway has not been defined. Complexity is increased by the likelihood that multiple pathways are involved (14, 15). However, it is dear that activation of NADPH oxidase culminates in assembly ofp47-phox and p67-phox with cytochrome bsss in the membrane (16-21). With the development of a cell-free system that models the assembly/activation process (3, 22-26) and the cloning of the NADPH oxidase components, it has been possible to begin addressing the structural features of the components involved. Structure of NADPH Oxidase Components. Cloning of the four NADPH oxidase components (27-32) has revealed that the predicted sequence of each protein is unique, with only limited regions of similarity to other known proteins. The gp91-phox subunit of cytochrome bsss has weak homology to NADPH and FAD binding sites found in the ferredoxin reductase family of flavoproteins (33-36). This suggests that cytochrome bsss may be a flavocytochrome, capable of cartying out the entire electron transfer from NADPH to O2. Recent modds (36, 37) postulate that a conformational change in gp91-phox is needed to either enhance NADPH binding and/or fadlitate dectron transfer between NADPH and FAD. Such a conformational change could be induced by assembly of the cytosolic components with the cytochrome. Experimental support for cytochrome bsss as a flavocytochrome has appeared from several laboratories (20, 33-35, 38, 39), although the modal is not universally accepted (40, 41). Several predicted structural features of p47-phox and p67phox also are of interest. The COOH-terminal region ofp47phox contains six to eight clustered putative phosphorylation sites. It has been shown that p47-phax is phosphoryhted during stimulation of intact neutrophils, yidding up to eight phosphospecies ranging from •pI 6.8 to 10 (42-44). Phosphorylation of the dustered sites could dramatically alter the conformation of the protein (43). However, direct evidence that phosphorylation of p47-phox is required for NADPH oxidase activation is lacking (45-48). Both p47-phox and p67phox contain another important structural feature, Src homology 3 (SH3) domains. Each protein contains two of these regions (Fig. 1). The newly described p40-phox also contains one SH3 region (10). SH3 domains were originally described

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1084/jem.180.6.2011

Cites

4 of 4 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 4 references

Cited by

Metadata

Authors
McPhail, L. C.
Venue
The Journal of experimental medicine
Published
1994-12-01
Volume
180
Issue
6
Pages
2011-2015
ISSN
  • 0022-1007 (ISSN-L)
  • 1540-9538
OpenAlex
W2032751204
Cited by
65
References
4
FWCI
4.02
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.